ZBH.SW Zimmer Biomet (SIX) pre-market 11 Feb 2026: Q4 sees CHF68.50 test

Zimmer Biomet Holdings, Inc. (ZBH.SW) opened pre-market at CHF68.50 after Q4 figures and management commentary. The focus keyword ZBH.SW stock matters today because the report and guidance will shape near-term flows on the SIX. Key headline metrics: EPS 3.14, PE 21.50, and market cap about CHF13.38B. We review the earnings, the market reaction, valuation, and what analysts and our models expect next for ZBH.SW stock.

Earnings recap: ZBH.SW stock Q4 numbers

Zimmer Biomet reported results tied to its Q4 earnings announcement dated 10 Feb 2026. The company delivered trailing EPS of 3.14 and the market is treating the release as a near-term catalyst for ZBH.SW stock. Revenue trends showed weakness year-over-year in fiscal 2025 with reported revenue contraction. The earnings print and any updated 2026 guidance are the primary drivers for trading volume and price action on SIX.

Market reaction and price action for ZBH.SW stock

Pre-market ZBH.SW stock sits at CHF68.50, down CHF2.00 or -2.84% from the prior close of CHF70.50. The share test is near the 52-week low area, with the year low at CHF67.50 and year high at CHF119.00. Short-term technicals show RSI 18.81 which is oversold. Expect higher volatility as the market digests guidance and model revisions.

Fundamentals and valuation for ZBH.SW stock

Zimmer Biomet’s key metrics show steady cash generation with free cash flow per share 6.73 and book value per share 64.52. Price-to-book is 1.36 and price-to-sales is 2.18. Debt metrics are notable: net debt to EBITDA roughly 2.87 and debt-to-equity 0.64. These ratios place ZBH.SW stock in a mid-cap, cash-generative healthcare device profile with moderate leverage versus peers.

Meyka grade and ZBH.SW stock forecast

Meyka AI rates ZBH.SW with a score out of 100: 72.54 (B+) — Suggestion: BUY. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly target of CHF56.70, compared with the current price CHF68.50, implying downside near -17.22%. These grades are not guaranteed and we are not financial advisors.

Risks and catalysts for ZBH.SW stock

Major catalysts include updated 2026 guidance, product approvals, and procedure volume recovery in key markets. Primary risks are slower procedure growth, margins under pressure, and higher interest cost given leverage. Inventory levels and days-of-inventory near 366.60 days warrant close monitoring as they affect working capital and cash flow for ZBH.SW stock.

Analyst targets, scenario outlook and trading notes on ZBH.SW stock

Analyst-style price targets we model for ZBH.SW stock: conservative CHF55.00, base CHF75.00, and bull CHF95.00. These reflect sensitivity to margin recovery and procedure volume. Watch relative sector performance where Healthcare devices have outperformed some peers year-to-date. For traders, low reported average volume but high relative volume flags possible gap moves near earnings. See latest after-hours movers for context source and our profile at ZBH.SW on Meyka.

Final Thoughts

Key takeaway: ZBH.SW stock opened pre-market at CHF68.50 after the Q4 release, and price action will hinge on guidance and margin detail. Fundamentals show solid cash flow with free cash flow per share 6.73 and a conservative balance sheet, yet the stock trades below its 50-day and 200-day averages at CHF78.58 and CHF87.90 respectively. Meyka AI’s forecast model projects a yearly target of CHF56.70, implying a -17.22% move from the current price. Use the model output and our B+ grade as one input among many. Earnings-driven volatility offers both risk and opportunity, so align position size to conviction and watch updates from Zimmer Biomet and sector peers for confirmation

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.